The anandamide synthetic analogue arachidonyl-2’-chloroethylamide (ACEA, Table 1) is a CB1R-selective compound, active in breast cancer stem cell invasiveness (Mohammadpour et al., 2017) but inactive in Kaposi’s sarcoma cells (Luca et al., 2009). Here, CNR1 is linked to breast cancer.